Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Major Depressive Disorder (MDD)
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder was shown to be associated with pathological alterations within neurotransmitter systems of the brain. Based on earlier study results, it is assumed that the neurotransmitter dopamine is relevant for several symptoms of depression, e.g., loss of interest or pleasure and lack of motivation. Thus, it is assumed that the synthesis of dopamine in the brain of depressed individuals could be impaired. The specific effect of common antidepressants on the human reward system in depression has not yet been sufficiently investigated. In particular, it is unclear whether depressed patients exhibit reward-specific changes of dopamine synthesis, and whether or not these changes can be differentially affected by diverse types of antidepressants. Neurotransmitter systems can be visualized in the brain using positron emission tomography (PET). Additionally, brain structure and function can be studied using magnetic resonance imaging (MRI). For the visualization of dopamine synthesis in the brain, the radioligand \[18F\]FDOPA can be used in PET measurements. To assess task-relevant changes of diverse radioligands and thus specific metabolic processes in the brain during specific tasks, a recently developed PET-approach can be used which has already been successfully applied in a pilot study with healthy volunteers. In the present project, 60 depressed subjects and 30 healthy controls will undergo PET/MR-imaging twice. Depressed subjects will be assigned to 1 of 2 treatment groups. 30 depressive subjects will receive bupropion, the other 30 patients will be treated with escitalopram. After a treatment period of 6 weeks, the 2nd PET measurement will be performed in all participants, aiming to detect potential reward-specific changes of dopamine synthesis. The investigators hypothesize that reward-specific changes of dopamine synthesis will be lower in depressed subjects than in healthy controls, that reward-specific changes of dopamine synthesis will be significantly higher in the bupropion group than in the escitalopram group, and that the changes of dopamine synthesis will be associated with functional changes in the brain (measured by simultaneous functional MRI scans). This will be the first study comparing the effects of escitalopram and bupropion on task-specific dopamine synthesis and thus on the human reward system. The study is expected to yield new insights for individual treatment concepts in the therapy of depression.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline — Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
  • Drug: Cipralex (escitalopram) — Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks

Primary Outcomes

  • Changes of the reward specific dopamine synthesis rate in the nucleus accumbens of depressed individuals after 6-8 weeks of antidepressant intake assessed via functional PET (6-8 weeks)
  • Relationship between potential changes of the reward-specific dopamine synthesis rate in the nucleus accumbens assessed via functional PET and treatment response in depressed individuals after 6-8 weeks of antidepressant intake (6-8 weeks)
  • Difference in changes to the reward-specific dopamine synthesis rate in the nucleus accumbens assessed via functional PET in depressed patients taking bupropion vs. escitalopram after 6-8 weeks of therapy (6-8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-12-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Vienna
Collaborators: Austrian Science Fund (FWF)
Contact Information
Study Contact:
Rupert Lanzenberger, Univ.-Prof. Priv.-Doz. Dr.
+43 1 40400 35760
rupert.lanzenberger@meduniwien.ac.at
Patricia Anna Handschuh, Dr.med.univ., BA
patricia.handschuh@meduniwien.ac.at
Rupert Lanzenberger, Univ.-Prof. Priv.-Doz. Dr.
+43 1 40400 35760
rupert.lanzenberger@meduniwien.ac.at
Medical University of Vienna
Interventions
  • Drug: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline — Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
  • Drug: Cipralex (escitalopram) — Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
Study Locations (1 sites)
Medical University of Vienna, Vienna, 1090 Austria
Eligibility Criteria
Inclusion Criteria: * Male and female subjects aged between 18-65 years of age * Depressive patients: DSM-IV diagnosis of MDD following SCID I, HDRS29, MADRS and BDI-II * Satisfactory general health as determined by past medical history, physical examination, vital signs at screening * Vital signs measured after 3 minutes resting in the supine position must be within the following ranges: oral body temperature between 35.0-37.5 °C, systolic blood pressure 90-140 mmHg, diastolic blood pressure 50-90 mm Hg, pulse rate 40-100 bpm * Subjects must weigh 50-100 kg to participate in this study with a BMI within 19-26. * Sufficient visual and auditory performance for neuropsychological testing * Written informed consent will be obtained prior to the start of any study procedures. Therefore, willingness and competence to sign the informed consent form is needed. * Potential patients must be able to communicate well with the investigator and comply with the requirements of the study * Only participants who are legally authorized to give informed consent will be included in the present study. Exclusion Criteria: * Depressed patients: Presence of any severe / unstable neurological, somatic or psychiatric comorbidity * Healthy controls: Any psychiatric disease or any severe / unstable neurological or somatic disease * Presence of psychotic symptoms * Acute suicidality * Any contraindication for magnetic resonance or PET imaging * Presence of any metallic implant in the head * History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to one of the study drugs or multiple study drugs (known hypersensitivity to bupropion, escitalopram) * Other clinically significant abnormality on physical, neurological, or laboratory examination or on electrocardiogram (ECG) that, in the opinion of the investigator precludes the patient from the study * Ingestion of antidepressants or other psychotropic agents within the last 6 months Previous escitalopram- or bupropion intake * Antidepressive trials wit DBS, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or Ketamine * Current smoking, substance abuse including alcohol, drugs of abuse, or any medication in a manner which is indicative of substance-related disorders (e.g. substance dependency) according to DSM-IV * Failure to comply with the study protocol or follow the instructions of the investigators * Positive urine pregnancy test * Known pregnancy or lactation * MRI scan that shows evidence of stroke, infarct, or other space occupying lesion or structural abnormality * History of any other drug or alcohol abuse or misuse * Participation in any clinical investigation within 12 weeks prior to dosing * Evidence from an Allen test of incomplete communication between the radial and ulnar artery, in either hand * Significant radiation exposure (\>5 mSv) in the frame of participation in trials within the past 10 years
Conditions Hypertension, Overweight, Obesity, Cardi...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Active Older Adults prospective cohort study examines the effects of a park-based fitness program on cardiovascular fitness outcomes for older adults (aged 50 years and older). Duke will perform a secondary analysis of the data collected as part of the Active Older Adults prospective cohort study run by Miami-Dade County Parks and Recreation.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Active older Adults — The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.

Primary Outcomes

  • Change in Body mass index (height and weight) (Baseline, 12 months, 36 months)
  • Change in blood pressure (Baseline, 12 months, 36 months)
  • Change in arm strength (Baseline, 12 months, 36 months)
  • Change in leg strength (Baseline, 12 months, 36 months)
  • Change in mobility (Baseline, 12 months, 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-06-15
Completion: 2026-06-16
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: Miami-Dade County Parks and Recreation
Principal Investigators:
  • Emily D'Agostino (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Emily M D'Agostino, DPH, MS, MEd, MA
emily.m.dagostino@duke.edu
Interventions
  • Behavioral: Active older Adults — The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.
Study Locations (1 sites)
Miami-Dade County Parks, Recreation and Open Spaces Department, Miami, Florida 33128 United States
Eligibility Criteria
Inclusion Criteria: * Aged 50 years or older, residing in Miami-Dade County * All participants enrolled in the Miami-Dade Active Older Adults study will be included in this secondary analysis Exclusion Criteria: * Aged less than 50 years, not residing in Miami-Dade County * Anyone not enrolled in the Miami-Dade Active Older Adults study will be excluded from this secondary analysis
Conditions Recurrent Breast Carcinoma
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study explores whether recurrent breast cancer can be safely treated with breast-conserving surgery and repeated radiation therapy in cases where patients have previously undergone radiation. Traditionally, recurrent breast cancer has been treated by removing the entire breast. However, recent research has shown that in certain situations, it may be possible to preserve the breast. The study will collect data on the safety of this treatment approach and its effects on patients. The treatment follows standard breast cancer care practices, involving 30 patients from Helsinki and Turku University Hospitals. Patients are carefully selected based on specific criteria, such as tumor size, localization, and prior treatment history. Special attention is given to the planning of radiation therapy and surgical techniques. The goal is to develop new treatment strategies that allow breast preservation even in cases of recurrent breast cancer, providing patients with high-quality and individualized care.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Breast conserving surgey and radiotherapy — The patients will undergo repeat Breast Conserving Surgery and Radiotherapy
  • Procedure: Mastectomy — The patients will undergo mastectomy

Primary Outcomes

  • A treatment-limiting radiation therapy complication. (From the beginning of the radiotherapy until 30 days after finishing the therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-01
Completion: 2030-12-31
Eligibility
Age: 55 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Turku University Hospital
Collaborators: Helsinki University Central Hospital
Contact Information
Study Contact:
Anselm Tamminen, MD, PhD
+3583130000
jlatam@utu.fi
Tuomo Meretoja, MD, PhD
+358504272 877
tuomo.meretoja@hus.fi
Helsinki University Hospital
Anselm Tamminen, MD, PhD
jlatam@utu.fi
Turku University Hospital
Interventions
  • Radiation: Breast conserving surgey and radiotherapy — The patients will undergo repeat Breast Conserving Surgery and Radiotherapy
  • Procedure: Mastectomy — The patients will undergo mastectomy
Study Locations (2 sites)
Helsinki University Hospital, Helsinki, Finland
Turku University Hospital, Turku, Finland
Eligibility Criteria
Inclusion Criteria: * The patient has a diagnosed breast cancer or tumor area in the breast with a maximum diameter of 3 cm, where a previous breast-conserving surgery has been performed (either invasive breast cancer or carcinoma in situ, DCIS). The patient has only a local recurrence, and imaging studies show no suspicion of metastases outside the breast (preoperative staging N0M0). At least 3 years have passed since the completion of prior radiation therapy. The new breast cancer can be technically treated with another breast-conserving surgery using a technique that does not require tissue transfer from areas opposite the removed tumor to restore the shape of the breast. The patient is at least 55 years old at the time of surgery. The patient is willing to participate in the study. The patient is capable of providing informed consent. Exclusion Criteria: * A booster dose, also known as a "boost," was administered during prior radiation therapy. Preoperative assessments suggest multifocal breast cancer, with the tumor area to be removed exceeding 3 cm. The planned radiation therapy per the study protocol cannot be administered due to factors such as shoulder joint stiffness, a pacemaker located in the radiation field, or a skin condition (e.g., scleroderma). The patient is unable to provide informed consent or is unwilling to participate in the study. Metastases outside the breast (e.g., axillary or distant metastases) are present.
Conditions Head and Neck Squamous Cell Carcinoma, C...
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the efficacy and safety profile of superficial hyperthermia (wIRA) in addition to standard of care (SOC) palliative radiotherapy in patients with inoperable/incurable locally advanced or recurrent/metastatic HNSCC or cutaneous SCC superficial tumours not suitable for radical treatment. The investigators will assess the best objective response rate (ORR) of patients with Inoperable/incurable or recurrent/metastatic HNSCC or cSCC with superficial lesion(s) treated with the combination of superficial hyperthermia (wIRA) and palliative radiotherapy.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Superficial hyperthermia — Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)

Primary Outcomes

  • Real-world implementation (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-14
Completion: 2028-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King's College London
Collaborators: Guy's and St Thomas' NHS Foundation Trust
Principal Investigators:
  • Anthony Kong (PRINCIPAL_INVESTIGATOR) - Clinical reader and honorary NHS consultant in clinical oncology
Contact Information
Study Contact:
Anthony Kong
44+2078486004
Anthony.Kong@kcl.ac.uk
Taylor McKenzie
44+2078486004
taylor.mckenzie@kcl.ac.uk
Anthony Kong
44 + 207-848-8302
Anthony.kong@kcl.ac.uk
Guy's and St. Thomas NHS Foundation Trust
Interventions
  • Device: Superficial hyperthermia — Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
Study Locations (2 sites)
Guy's and St. Thomas NHS Foundation Trust, London, SE1 9RT United Kingdom
Guy's Cancer Centre, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Patient with histologically confirmed incurable or inoperable cancers with disease \[at least one superficial lesion(s) or lymph node(s)\] suitable for hydrosun® TWH1500 treatment 2. Patient undergoing standard of care palliative radiotherapy (suitable with the pre-specified dose and fractionation in the protocol 3. Aged ≥18 years old 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 5. Patient with capacity to consent Exclusion Criteria: 1. No superficial tumour lesion or lymph node that is suitable for hydrosun® TWH1500 treatment. 2. Patients are not suitable for one of the pre-specified palliative radiotherapy dose and fractionation 3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

Graded Insulin Suppression Test P&F

NCT06592261
Recruiting
Conditions Insulin Resistance, Hyperinsulinemia, Ob...
Phase PHASE1
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a "graded insulin suppression test" ("GIST"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia) — Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
  • Drug: Insulin regular, 32 mU/m2/min (hyperinsulinemia) — Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
  • Drug: Octreotide Acetate, 6-45 ng/kg/min — Suppression of endogenous insulin secretion
  • Drug: Dextrose 20 % in Water — Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
  • Drug: Glucagon, 0-0.5 ng/kg/min — Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)

Primary Outcomes

  • Steady-state plasma glucose at euinsulinemia (ESS-G) (150-180 minutes during GIST protocol)
  • Steady-state plasma glucose at hyperinsulinemia (HSS-G) (270-300 minutes during GIST protocol)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-09-16
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: University of Pisa
Principal Investigators:
  • Joshua R Cook, MD, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Joshua R Cook, MD, PhD
2123056289
jrc2175@cumc.columbia.edu
Ishwari Nagnur
2123059336
imn2113@cumc.columbia.edu
Joshua R Cook, MD, PhD
2123059336
jrc2175@cumc.columbia.edu
Columbia University Irving Medical Center
Interventions
  • Drug: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia) — Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
  • Drug: Insulin regular, 32 mU/m2/min (hyperinsulinemia) — Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
  • Drug: Octreotide Acetate, 6-45 ng/kg/min — Suppression of endogenous insulin secretion
  • Drug: Dextrose 20 % in Water — Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
  • Drug: Glucagon, 0-0.5 ng/kg/min — Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
Study Locations (1 sites)
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Body mass index of 18-25 and 30-45 kg/m2 * Able to understand written and spoken English and/or Spanish * Fasting euinsulinemia (fasting serum insulin of 4-10 μU/mL) for reference group or hyperinsulinemia (fasting serum insulin ≥ 13 μU/mL) for hyperinsulinemic group on screening labs * Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations. Exclusion Criteria: * Unable to provide informed consent in English or Spanish * Unwillingness to use only bedpan or urinal to void or to refrain from non-emergent mobile device use during the GIST * Documented weight loss of ≥ 5% of baseline within the previous 6 months * Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg, and/or * Diastolic blood pressure \< 60 mm Hg or \> 100 mm Hg * Abnormal resting heart rate: \< 60 or ≥ 110 bpm * Sinus brady or tachycardia that has been worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion * Abnormal screening electrocardiogram (or if on file, performed within previous 90 d): * Non-sinus rhythm * Heart conduction blocks * Previously unknown ischaemic changes that persist on repeat EKG: * ST elevations * T-wave inversions in a vascular distribution * Hemoglobin A1c ≥ 5.7%, and/or * Fasting plasma glucose ≥ 100 mg/dL * Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential * Positive urine drug screen, except for lawfully prescribed medications and/or marijuana, provided that participant agrees to refrain from marijuana use during the period that they refrain from alcohol. * Transaminases (AST or ALT) \> 3.0 x the upper limit of normal * Total bilirubin \> 1.25 x the upper limit of normal * Abnormal sodium, potassium, chloride, or bicarbonate levels that are considered potentially significant according to the clinical judgment of the PI. * Creatinine equating to estimated glomerular filtration rate \< 60 mL min-1 1.73 m-2 * Hemoglobin \< 10 g/dL or hematocrit \< 30% * Platelet count \< 100,000/μL * Women currently pregnant, measured by serum and/or urine β-hCG * Women currently breastfeeding * History of having met any of the American Diabetes Association's definitions of prediabetic state during adulthood or diabetes mellitus (i.e., overt diabetes) at any time: * Hemoglobin A1c ≥ 5.7%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency * Plasma glucose ≥ 100 mg/dL after 8-h fast * Plasma glucose of ≥ 140 mg/dL at 2 h after ingestion of a 75-g glucose load * Random plasma glucose ≥ 200 mg/dL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state * History of gestational diabetes mellitus within the previous 5 years * Use of most antidiabetic medications within the 30 days prior to screening * Excluded: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening * Known, documented history, at the time of screening, of any of the following medical conditions: * Pancreatic pathology, including but not limited to: Pancreatic neoplasia (unless appropriately evaluated and considered benign and not producing hormones), Chronic pancreatitis, History of acute pancreatitis within the past 5 years * Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary) * Atherosclerotic cardiovascular disease * Stable or unstable angina * Myocardial infarction * Ischaemic or hemorrhagic stroke * Peripheral arterial disease (claudication) * Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor) * History of percutaneous coronary intervention * Heart rhythm abnormalities (non-sinus) * Congestive heart failure of any New York Heart Association class * Severe valvular heart disease (e.g., aortic stenosis) * Pulmonary hypertension * Chronic kidney disease, Stage 3 or higher (estimated glomerular filtration rate \< 60 mL/min/1.73 m2), of any cause * Advanced or severe liver disease, including but not limited to: * Advanced liver fibrosis, as determined by non-invasive testing * Cirrhosis of any etiology * Autoimmune hepatitis or other rheumatologic disorder affecting the liver * Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis) * Hepatocellular carcinoma * Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease) * Gallstone disease, including: * Biliary colic (active) * History of acute cholecystitis not treated with cholecystectomy * History of other gallstone complications (e.g., pancreatitis, cholangitis) * Chronic viral illness (N.B. diagnosis based only on medical history and not by laboratory confirmation) * Hepatitis B virus (HBV), unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 30 d prior to screening * Hepatitis C virus (HCV) infection, unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 30 d prior to screening * Human immunodeficiency virus (HIV) infection * Active seizure disorder (including controlled with antiepileptic drugs) * Psychiatric diseases causing functional impairment that: * Are or have been decompensated within 1 year of screening, and/or * Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine), monoamine oxidase inhibitors, tricyclic antidepressants, or lithium * Other endocrinopathies: * Cushing syndrome (okay if considered in remission after treatment, provided that no exogenous corticosteroids or other ongoing treatment are required) * Adrenal insufficiency * Primary aldosteronism * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation * Bleeding disorders, including due to anticoagulation, or significant anemia * Active malignancy, or hormonally active benign neoplasm, except allowances for: * Non-melanoma skin cancer * Differentiated thyroid cancer (AJCC Stage I only) * Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above * Clinical concern for increased risk of hypokalemia, including low potassium on screening labs (i.e., below lower limit of normal), use of certain medications, or any medical conditions listed above * Use of prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for: * Use of drugs prescribed for indications other than the exclusionary diagnoses/purposes listed above (e.g., antiepileptic drugs used for non-seizure indications, ACEi/ARB used for uncomplicated hypertension rather than for congestive heart failure, etc.). Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded. * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted. * Beta blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) * History of certain weight-loss (bariatric) surgery, including: * Roux-en-Y gastric bypass * Biliopancreatic diversion * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months * Clinical concern for alcohol overuse, including recent documented history during screening and/or participant report of regularly consuming more t
Conditions Resting Heart Rate, Blood Glucose Contro...
Phase NA
Enrollment 3200
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Ambient air temperatures in Asian, Latin American, African, and Pacific climate hotspots have broken record highs in 2024, driven by man-made climate change. Solutions are needed to reduce heat exposure in communities. Sunlight-reflecting cool roof coatings passively reduce indoor temperatures and energy use to protect home occupants from extreme heat. Occupants living in poor housing conditions globally - for example in informal settlements, slums, and low-socioeconomic households - are especially vulnerable to increased indoor heat exposure. Heat exposure can instigate and worsen numerous physical, mental and social health conditions. The worst adverse health effects are being experienced in communities least able to adapt to heat exposure. By reducing indoor temperatures, cool roof use can promote physical, mental and social wellbeing in occupants. The long-term research goal is to identify viable passive housing adaptation technologies with proven health and environmental benefits to reduce the burden of heat stress in communities affected by heat globally. To meet this goal, the investigators will conduct a cluster-randomized controlled trial to establish the effects of cool roof use on health, indoor environment and economic outcomes in five urban climate hotspots: Ouagadougou, Burkina Faso; Colima, Mexico; Ahmedabad, India; Niue; and Tavua, Fiji.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: Cool roof — Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).

Primary Outcomes

  • Resting heart rate (Eight measurements will be taken: one at baseline and seven over 12 months, covering three consecutive hottest months and four alternate months.)
  • Blood glucose control (Two measurements will be taken: one at baseline and one in the last month of three consecutive hottest months.)
  • Depression (Eight measurements will be taken: one at baseline and seven over 12 months, covering three consecutive hottest months and four alternate months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-04
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 3200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aditi Bunker
Collaborators: Sika Services AG, SOPREMA, Engineered Polymer Solutions (EPS B.V.), Resene, Pacific Community, Habitat for Humanity, The Tindall Foundation, Rutgers University, Boston University, London School of Hygiene and Tropical Medicine, Heidelberg University, University of Ouagadougou, Burkina Faso, Indian Institute of Public Health, India, Fiji National University, Universidad de Colima
Principal Investigators:
  • Collin Tukuitonga, Sir. Dr. (PRINCIPAL_INVESTIGATOR) - University of Auckland, New Zealand
Contact Information
Study Contact:
Aditi Bunker, Dr
+49 6221 565344
aditi.bunker@uni-heidelberg.de
Collin Tukuitonga, Sir. Dr.
+6493737599
collin.tukuitonga@auckland.ac.nz
Donald Wilson
+6798053931
donald.wilson@fnu.ac.fj
Fiji National University
Interventions
  • Other: Cool roof — Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
Study Locations (5 sites)
University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Fiji National University, Suva, Fiji
Indian Institute of Public Health Gandhinagar, Ahmedabad, Gandhinagar India
Instituto Tecnológico de Hermosillo, Hermosillo, Sanora Mexico
Niue, Alofi, Niue
Eligibility Criteria
Inclusion Criteria: * Permanent household resident. Exclusion Criteria: * Roof damage, inaccessible or instability of roof adversely affecting cool roof coating application. * Participant unable to provide written/verbal informed consent.
Conditions Advanced Breast Cancer
Phase PHASE2
Enrollment 190
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To compare the efficacy and safety of ribociclib in combination with aromatase inhibitor and physician's choice of chemotherapy sequential endocrine therapy in the first-line treatment of ER medium to low expression/HER2-negative advanced breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ribociclib combined with AI±OFS — Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
  • Drug: physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS — Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.

Primary Outcomes

  • Progression Free Survival (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-08-13
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 190 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Yidu Central Hospital of Weifang, Affiliated Hospital of Jiangnan University, The Affiliated Jiangyin Hospital of Southeast University Medical College
Contact Information
Study Contact:
Yongmei Yin, Ph.D
025-68307102
ymyin@njmu.edu.cn
Wei Li, Ph.D
025-68306360
real.lw@163.com
Jiangsu Provincial People's Hospital
Interventions
  • Drug: Ribociclib combined with AI±OFS — Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
  • Drug: physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS — Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
Study Locations (1 sites)
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Patient is an adult female ≥ 18 years old at the time of informed consent. 2. ECGO rating 0-2. 3. Histologically confirmed recurrent or metastatic breast cancer, including patients initially diagnosed as stage IV or locally advanced inoperable patients. 4. Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory. ER should express in the range of 10% to 50%. ER positive by local laboratory testing. 5. Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1 + or 2 + If IHC is 2 +, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample. 6. Determination by the physician that the patient is in a rapid disease progression situation: * Symptomatic visceral metastases * Rapid progression of disease or impending visceral compromise. * Markedly symptomatic non visceral disease if the treating physician opt to give chemotherapy for rapid palliation of patients symptoms. 7. Patient hasn't received systemic anti-cancer therapy at the stage of recurrence/metastasis. 8. Patient must have at least one measurable lesion (according to RECIST 1.1 criteria) 9. Postmenopausal or pre/perimenopausal female patients are eligible for enrolment; pre or perimenopausal female patients must be willing to receive LHRHa during the study period. 10. All patients were required to meet the following laboratory biochemical values prior to enrolment: * Haematology: Hb ≥90 g/L, WBC ≥3.5×109/L, ANC ≥1.5×109/L, PLT ≥100×109/L; * Renal function: serum creatinine ≤ upper limit of normal value; * Liver function: for those without liver metastases, AST, ALT, ALP ≤2.5 times the upper limit of normal values, and ≤1.25 x the upper limit of normal values for total bilirubin; for those with liver metastases, AST, ALT, ALP ≤ 5 times the upper limit of normal value, and total bilirubin ≤ 1.5 x upper limit of normal value. Exclusion Criteria: 1. Patient has received systemic anti-cancer therapy at the stage of recurrence/metastasis. 2. Those who have been treated with CDK4/6 inhibitors in the neoadjuvant/adjuvant phase. 3. Patients those with symptomatic CNS metastases. 4. Patient has a history of clinically symptomatic cardiovascular, hepatic, respiratory, renal and haemato-endocrine system or neuropsychiatric disorders. 5. Patient has a serious concomitant disease, such as an infectious disease; has multiple factors that affect the oral administration and absorption of the drug. 6. Pregnant or lactating women (women of childbearing age must have had a negative pregnancy test within 14 days prior to the first dose; if positive, pregnancy must be ruled out by ultrasound). 7. Patients in poor general condition who cannot tolerate chemotherapy treatment. 8. The investigator considers the patient unsuitable for entry into this study.
Conditions Type 2 Diabetes
Phase NA
Enrollment 235
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A pilot study carried out by the company ALPHA-MOS in 2017-19 showed that the analysis of volatile organic compounds contained in exhaled air could reliably predict blood glucose levels. Subsequently, the company BOYDSense, a subsidiary of ALPHA-MOS, produced the Module In a Box prototypes of portable, non-invasive volatile organic compounds analyzers that could be equipped with an on-board algorithm estimating blood glucose levels. The Toulouse University Hospital conducted the BOYDSENSE-GM study in 2021-2023, in partnership with BOYDSense, aiming to develop the first algorithm for calculating blood glucose levels based on the analysis of the breath of 100 patients living with type 2 diabetes and to carry out a first performance test of the Module In a Box prototype in 30 additional subjects with type 2 diabetes. These recent results confirmed the potential of this innovative blood glucose measurement technology and gave the first indications about the next developments needed to improve its performances. The characteristics of the air exhaled by a human are impossible to simulate. Therefore, further development of the glucose calculation algorithm requires the production of additional clinical data, supporting the carrying out of the present study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Exhaled air analysis — The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.

Primary Outcomes

  • Measurements of volatile organic compounds (19 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-11
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 235 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Toulouse
Principal Investigators:
  • Pierre Gourdy, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Toulouse
Contact Information
Study Contact:
Pierre Gourdy, MD
0561323740
gourdy.p@chu-toulouse.fr
Laurent Cazals
0561323361
cazals.l@chu-toulouse.fr
Pierre Gourdy, MD
0561323218
gourdy.p@chu-toulouse.fr
Fontaine Salée Hospital
Interventions
  • Other: Exhaled air analysis — The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
Study Locations (2 sites)
Fontaine Salée Hospital, Salies-du-Salat, France 31 260 France
Rangueil Hospital, Toulouse, France 31059 France
Eligibility Criteria
Inclusion Criteria: * Patient living with type 2 diabete or non-diabetic individuals characterized by overweight/obesity (Body Mass Index \>= 25Kg/m²) , admitted in the two departments of the Toulouse University Hospital (Diabetology, Metabolic Diseases and Nutrition as well as Endocrinology, Metabolic Diseases and Nutrition). * Aged 18 years or more. * Ability to sign informed consent. * Affiliation to a social security scheme. Exclusion Criteria: * Ongoing respiratory infection. * Pregnancy or breastfeeding. * Patient under guardianship, curatorship or safeguard of justice.
Conditions Major Depressive Episode, Risk Reduction...
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a highly prevalent and disabling mental health problem. One way of preventing depression is to stop it before it happens through effective self-management. Working with potential users, a coach-guided, personalized depression risk communication tool (PDRC) was developed for sharing information about individualized depression risk, risk profile (risk factors present), potential risk reduction and evidence-based self-help strategies. It is anticipate that the PDRC will greatly motivate users to actively engage in self-help and help seeking, leading to a reduced risk of depression. The proposed study will recruit 500 male and 500 female adults who are at high risk of having depression across Canada, and randomly allocate them into the intervention and control groups. Participants will be followed for 12 months. The data of the trial will allow us to answer the questions: (1) Can the coach-guided PDRC reduce the risk of depression? (2) Does the intervention motivate people to actively engage in evidence-based self-help and help-seeking behaviors? (3) For whom the intervention works best? and (4) what are the costs and potential savings associated with the intervention? If successful, this project will offer a novel and effective tool for early prevention of major depression in the Canadian general population, help us understand how it works and the cost-effectiveness of implementing such a tool in the community from the economic perspective.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Other: coach-guided personalized depression risk communication — see information in arm description.
  • Other: depression risk information — see information in arm description.

Primary Outcomes

  • The proportion of major depressive episode cases (12 months after randomization.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-10
Completion: 2029-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dalhousie University
Principal Investigators:
  • JianLi Wang, PhD (PRINCIPAL_INVESTIGATOR) - Dalhousie University
Contact Information
Study Contact:
Jianli Wang, PhD
902-473-6684
jianli.wang@dal.ca
JianLi Wang, PhD
9024943575
jianli.wang@dal.ca
Faculty of Medicine
Interventions
  • Other: coach-guided personalized depression risk communication — see information in arm description.
  • Other: depression risk information — see information in arm description.
Study Locations (1 sites)
Faculty of Medicine, Halifax, Nova Scotia B3H 1V7 Canada
Eligibility Criteria
Inclusion Criteria: * no MDE at baseline, or full remission for 2 months for those who had a past MDE (see below the question). * Aged 18 and 65 years. * At high risk of MDE based on the depression risk calculators (predicted risk of 6.5%+ for males and 11.2%+ for females), which represent the top two deciles of male and female populations in Canada. * Agreement to be contacted for follow-up assessments, and * no language barriers to English or French Exclusion Criteria: individuals who * cannot provide informed consent, * do not agree to be followed, * cannot communicate in English and French, or * report suicide behaviors (score \&gt;0 on item 9 of the Patient Health Questionnaire (PHQ-9)).
Conditions Major Depression Disorder, Depression
Phase PHASE1
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: DMT-Medium Dose — 14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.
  • Drug: DMT-Low Dose — 10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes
  • Drug: THC-Medium Dose — 0.5 mg over 5 minutes and then 2 mg over and 55 minutes
  • Drug: THC-Low Dose — 0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

Primary Outcomes

  • Safety of Physiological indices (Time Frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day.)
  • Psychedelic Effects (From start Test Day Time points (Minutes): -60, +30, +120.)
  • Psychotomimetic Effects (Test Day Time points (Minutes): -60, +30, +120)
  • Anxiety (Test Day Time points (Minutes): -60, +30, +120)
  • Depression (From start of test day (-60), +30, and +120.)
  • Intensity of the Experience (Test Day Time points (Minutes): +150 - +180)
  • Drug Reinforcing Effects (Test Day Time points (Minutes): +120)
  • Tolerability of Overt Adverse Effects (Test Day Time points (Minutes): -60, +30, +120, 180 (end of test day))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-03-14
Completion: 2027-12-01
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Deepak C. D'Souza
Principal Investigators:
  • Deepak D'Souza, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Deepak C D'Souza, MD
(203) 932-5711
deepak.dsouza@yale.edu
Deepak C D'Souza, MD
203-932-5711
deepak.dsouza@yale.edu
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,
Interventions
  • Drug: DMT-Medium Dose — 14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.
  • Drug: DMT-Low Dose — 10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes
  • Drug: THC-Medium Dose — 0.5 mg over 5 minutes and then 2 mg over and 55 minutes
  • Drug: THC-Low Dose — 0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes
Study Locations (1 sites)
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven, Connecticut 06516 United States
Eligibility Criteria
Some Common Inclusion Criteria: 1. Males and females 2. Age 21 to 65 years 3. Body mass index between 18-35 kg/m2 4. Willing to refrain from taking any medications not approved by the study physician 5. Willing to refrain from using street drugs and alcohol 6. Negative urine drug screen 7. Willing and able to abstain from smoking throughout each test session 8. Women who are of child-bearing potential (WOCBP) and sexually active must be willing to practice an effective means of birth control 9. Willing not to drive to and from the testing session Some Inclusion Criteria for Subjects with MDD: 1. Diagnosed with Major Depressive Disorder (MDD) 2. Unsatisfactory response to antidepressants 3. Engaged in treatment for depression with a clinician and willing to continue treatment for the duration of the study 4. Not engaged in treatment 5. Consent to allow the research team to communicate with mental health provider. 6. Only subjects who get support for participation in the trial from their mental health clinician will be eligible to be enrolled in the study Some Common Exclusion Criteria: 1. Medications that might significantly interfere with the effects of the study medications 2. Cognitive dysfunction that could interfere with study participation 3. Alcohol or substance use disorder 4. Any lifetime history of hallucinogen use disorder 5. Regular use or misuse of hallucinogens 6. History of intolerance to perceptual altering drugs 7. Significant blood pressure problems 8. Pregnancy or currently breast feeding (lactation) 9. Any unstable medical conditions 10. Significant cardiovascular disease 11. Significantly abnormal laboratory test results 12. History of serotonin syndrome Some Exclusion criteria for MDD subjects: 1. Current primary psychiatric disorder other than MDD 2. Medically significant condition rendering unsuitability for the study Some Exclusion criteria for healthy controls: 1. No current DSM-V psychiatric disorder, excluding nicotine and caffeine use disorder 2. No family history of serious mental illness (e.g., schizophrenia, bipolar disorder) Some Inclusion criteria for healthy controls: 1. No current DSM-5 psychiatric disorder, excluding nicotine and caffeine use disorder 2. No lifetime use of psychiatric medication \>3 months (proxy for psychiatric disorders)
Conditions Anxiety, Depression, Stress, Wellbeing, ...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to provide a free 6-week, online psychological coaching program to NSU undergraduate students to help with anxiety, depression, and stress, while improving quality of life and healthy coping skills.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: online mental health coaching — SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency

Primary Outcomes

  • Participant anxiety symptom severity (From enrollment up to 24 weeks)
  • Participant depression symptoms severity (From enrollment up to 24 weeks)
  • Participant difficulties with emotion regulation (From enrollment up to 24 weeks)
  • Participant Stress levels (From enrollment up to 24 weeks)
  • Participant Resiliency (From enrollment up to 24 weeks)
  • Participant quality of life and life satisfaction (From enrollment up to 24 weeks)
  • Participant adaptive coping (From enrollment up to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-13
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Southeastern University
Principal Investigators:
  • Kayla Thayer, Ph.D., ABPP (PRINCIPAL_INVESTIGATOR) - Nova Southeastern University
Contact Information
Study Contact:
Principal Investigator
954-262-5880
kthayer@nova.edu
Principal Investigator
954-262-5880
kthayer@nova.edu
Nova Southeastern University
Interventions
  • Behavioral: online mental health coaching — SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
Study Locations (1 sites)
Nova Southeastern University, Fort Lauderdale, Florida 33301 United States
Eligibility Criteria
Inclusion Criteria: * Currently matriculating NSU undergraduate students (ages 18+) Exclusion Criteria: * Students who are not current NSU undergrads, participants aged 17 and younger, students who are currently enrolled in psychotherapy or mental health services, or students with acute mental health needs (e.g., psychosis, active alcohol or substance use problems, suicidality)
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired. For example, they might not be able to walk or process information as quickly, and they might have problems with their working memory. Psychomotor slowing in LLD might be the result of a problem with the way a person's body produces or responds to the neurotransmitter dopamine. The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect psychomotor slowing in LLD. Methods In this study, participants are adults aged 60 years or older with moderate to severe major depression. Participants undergo the "L-DOPA challenge"-a 2-week period where they receive a dose of L-DOPA once a day for the first week and a dose of L-DOPA twice a day for the second week. Before and after a participant completes the L-DOPA challenge, the study team assesses their depressive symptoms and psychomotor function. After the L-DOPA challenge, if a participant still shows signs of moderate or severe depression, they receive an antidepressant for 12 weeks. Aims The first aim of this study is to test the feasibility of the L-DOPA challenge-that is, whether most of the 50 participants recruited for this study will complete the L-DOPA challenge. For example, participants might have to withdraw if they can't make the daily visits to the research site to receive their L-DOPA medication, if they can't tolerate the medication's side effects, or if their depressive symptoms get significantly worse. Our hypothesis is that 80% of the participants will complete the L-DOPA challenge. The second aim of the study is to see if L-DOPA affects participants' depressive symptoms, processing speed, and working memory. Our hypothesis is that L-DOPA response, measured as an improvement in gait speed, is associated with a decrease in depressive symptoms and an increase in processing speed and working memory.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Apo-levocarb — As above.

Primary Outcomes

  • L-DOPA challenge completion rate (6 months)
  • Depressive symptoms (At 2, 3, 7, and 15 weeks from baseline)
  • Gait speed (At baseline and 2 weeks from baseline)
  • Psychomotor speed (At baseline and 2 weeks from baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-08-15
Completion: 2026-05-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Collaborators: Providence Health & Services
Contact Information
Study Contact:
Nicholas J Ainsworth, MD
6048069090
nainsworth@providencehealth.bc.ca
Nicholas J Ainsworth, MD
6048069090
nainsworth@providencehealth.bc.ca
St. Paul's Hospital
Interventions
  • Drug: Apo-levocarb — As above.
Study Locations (1 sites)
St. Paul's Hospital, Vancouver, British Columbia V6Z 1Y6 Canada
Eligibility Criteria
Inclusion Criteria: * Outpatient persons capable of providing informed consent * Minimum age of 60 years old * MINI International Neuropsychiatric Interview diagnosis of major depressive disorder, based on DSM-5 criteria * MADRS score of ≥15 (moderate/severe depression) * On stable doses of psychotropic medication, including antidepressant medication, for at least 4 weeks * Able to adhere to the intervention schedule Exclusion Criteria: * Current diagnosis of major neurocognitive disorder * Current active psychosis * Unstable medical illness, including clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma), or renal disease * Diagnosis of narrow angle glaucoma * Suspicious, undiagnosed skin lesions or a history of melanoma * History of myocardial infarction * Atrial, nodal, or ventricular arrhythmias * History of seizures or seizure disorder * History of peptic ulcer disease * History of allergy or other hypersensitivity to levodopa, carbidopa, or to any other ingredient in the formulation of Levocarb * Active suicidal ideation * Psychotropic medication initiation or dose change \<4 weeks prior to enrolment * Regular use of dopamine antagonist or benzodiazepines ≥2mg lorazepam equivalent per day * Unable to complete neuropsychological testing in the English language * Have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests) * History of falls, with ≥1 fall per week during the past 4 weeks